Online inquiry

IVTScrip™ mRNA-Human ARL6IP4, (Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WK24748MR)

This product GTTS-WK24748MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the ARL6IP4 protein. This product can be used in Retinoid acid signaling-responsive fetal germ cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Human
RefSeq NM_001002251.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 51329
UniProt ID Q66PJ3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ARL6IP4, (Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WK24748MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK15202MR IVTScrip™ mRNA-Human ANKRD16, (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ANKRD16
GTTS-WK23273MR IVTScrip™ mRNA-Human ARPP19, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARPP19
GTTS-WK25927MR IVTScrip™ mRNA-Human ARID5A, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARID5A
GTTS-WK22011MR IVTScrip™ mRNA-Human ARHGEF18, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARHGEF18
GTTS-WK7747MR IVTScrip™ mRNA-Human ADGRL3, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADGRL3
GTTS-WK22016MR IVTScrip™ mRNA-Human ARHGEF3, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARHGEF3
GTTS-WK3428MR IVTScrip™ mRNA-Human D105, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA D105
GTTS-WK25606MR IVTScrip™ mRNA-Human ARHGEF1, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARHGEF1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW